In this issue:
5-year data for 1- versus 3-week radiotherapy for local cancer control
Pembrolizumab plus neoadjuvant chemotherapy for early-stage breast cancer
Patient-reported outcomes for atezolizumab in metastatic TNBC
Pertuzumab, trastuzumab, and docetaxel for HER2+ metastatic patients
HER2 peptide vaccines to prevent recurrence
MK-2206 plus chemotherapy for HER2+/HR- breast cancer
Recurrence risk after neoadjuvant chemotherapy
Tailoring adjuvant endocrine therapies for premenopausal women
Dietary AGEs and breast cancer risk
Impact of dietary modification on breast cancer deaths
Please login below to download this issue (PDF)